Literature DB >> 19427492

The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress.

Camila Manrique1, Guido Lastra, Michael Gardner, James R Sowers.   

Abstract

The relationship between HTNand other components of the CMSis complex. However, there is growing evidence that enhanced activation of the RAAS is a key factor in the development of endothelial dysfunction and HTN. Insulin resistance is induced by activation of the RAAS and resulting increases in ROS. This insulin resistance occurs in cardiovascular tissue and in tissues traditionally considered as targets for the action of insulin, such as muscle and liver. Indeed, there is a mounting body of evidence that the resultant insulin resistance in cardiovascular tissue and kidneys contributes to the development of endothelial dysfunction, HTN, atherosclerosis, CKD, and CVD.77 RAAS-associated signaling by way of the AT1R and MR, triggers tissue activation of the NADPH oxidase enzymatic activation and increased production of ROS. Oxidative stress in cardiovascular tissue is derived from both NADPH oxidase and mitochondrial generation of ROS, and is central to the development of insulin resistance, endothelial dysfunction, HTN, and atherosclerosis. Pharmacologic blockade of the RAAS not only improves blood pressure, but alsohas a beneficial impact on inflammation, oxidative stress, insulin sensitivity, and glucose homeostasis. Several strategies are available for RAAS blockade, including ACE inhibitors, ARBs, and MR blockers, which have been proven in the clinical trials to result in improved CVD and CKD outcomes. New research in these areas will allow for a better understanding of the relationship between HTN, insulin resistance, and activation of the RAAS, which could result in newer alternatives for a more comprehensive management of HTN in the setting of the CMS..

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19427492      PMCID: PMC2828938          DOI: 10.1016/j.mcna.2009.02.014

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  77 in total

1.  Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by mircomolar concentrations of alpha-lipoic acid.

Authors:  B A Maddux; W See; J C Lawrence; A L Goldfine; I D Goldfine; J L Evans
Journal:  Diabetes       Date:  2001-02       Impact factor: 9.461

Review 2.  Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions.

Authors:  G Grassi
Journal:  J Hypertens       Date:  2001-10       Impact factor: 4.844

Review 3.  Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why).

Authors:  L Landsberg
Journal:  J Hypertens       Date:  2001-03       Impact factor: 4.844

4.  Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response.

Authors:  R A Beswick; H Zhang; D Marable; J D Catravas; W D Hill; R C Webb
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

5.  Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes.

Authors:  E M Mervaala; Z J Cheng; I Tikkanen; R Lapatto; K Nurminen; H Vapaatalo; D N Müller; A Fiebeler; U Ganten; D Ganten; F C Luft
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

6.  HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.

Authors:  S Wassmann; U Laufs; A T Bäumer; K Müller; K Ahlbory; W Linz; G Itter; R Rösen; M Böhm; G Nickenig
Journal:  Hypertension       Date:  2001-06       Impact factor: 10.190

7.  Angiotensin converting enzyme inhibition improves cardiac neuronal uptake of noradrenaline in spontaneously hypertensive rats.

Authors:  W Raasch; S Betge; A Dendorfer; T Bartels; P Dominiak
Journal:  J Hypertens       Date:  2001-10       Impact factor: 4.844

8.  Ramipril and the development of diabetes.

Authors:  S Yusuf; H Gerstein; B Hoogwerf; J Pogue; J Bosch; B H Wolffenbuttel; B Zinman
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

9.  Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice.

Authors:  F E Rey; M E Cifuentes; A Kiarash; M T Quinn; P J Pagano
Journal:  Circ Res       Date:  2001-08-31       Impact factor: 17.367

10.  Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta.

Authors:  M Yuan; N Konstantopoulos; J Lee; L Hansen; Z W Li; M Karin; S E Shoelson
Journal:  Science       Date:  2001-08-31       Impact factor: 47.728

View more
  59 in total

Review 1.  Noncoding RNAs in Cardiovascular Disease: Pathological Relevance and Emerging Role as Biomarkers and Therapeutics.

Authors:  Roopesh S Gangwar; Sanjay Rajagopalan; Rama Natarajan; Jeffrey A Deiuliis
Journal:  Am J Hypertens       Date:  2018-01-12       Impact factor: 2.689

2.  Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension.

Authors:  Sergey V Nedogoda; Alla A Ledyaeva; Elena V Chumachok; Vera V Tsoma; Galina Mazina; Alla S Salasyuk; Irina N Barykina
Journal:  Clin Drug Investig       Date:  2013-08       Impact factor: 2.859

3.  THE RENIN-ANGIOTENSIN SYSTEM AND THE BIOLOGY OF SKELETAL MUSCLE: MECHANISMS OF MUSCLE WASTING IN CHRONIC DISEASE STATES.

Authors:  Patrice Delafontaine; Tadashi Yoshida
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

4.  Angiotensin II induced catabolic effect and muscle atrophy are redox dependent.

Authors:  Laura C Semprun-Prieto; Sergiy Sukhanov; Tadashi Yoshida; Bashir M Rezk; Romer A Gonzalez-Villalobos; Charlotte Vaughn; A Michael Tabony; Patrice Delafontaine
Journal:  Biochem Biophys Res Commun       Date:  2011-05-06       Impact factor: 3.575

Review 5.  Metabolic phenotyping for discovery of urinary biomarkers of diet, xenobiotics and blood pressure in the INTERMAP Study: an overview.

Authors:  Queenie Chan; Ruey Leng Loo; Timothy M D Ebbels; Linda Van Horn; Martha L Daviglus; Jeremiah Stamler; Jeremy K Nicholson; Elaine Holmes; Paul Elliott
Journal:  Hypertens Res       Date:  2016-12-22       Impact factor: 3.872

6.  Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat.

Authors:  Camila Manrique; Guido Lastra; Javad Habibi; Lakshmi Pulakat; Rebecca Schneider; William Durante; Roger Tilmon; Jenna Rehmer; Melvin R Hayden; Carlos M Ferrario; Adam Whaley-Connell; James R Sowers
Journal:  Metabolism       Date:  2011-06-02       Impact factor: 8.694

7.  Mitochondria and Oxidative Stress in the Cardiorenal Metabolic Syndrome.

Authors:  Annayya R Aroor; Chirag Mandavia; Jun Ren; James R Sowers; Lakshmi Pulakat
Journal:  Cardiorenal Med       Date:  2012-02-07       Impact factor: 2.041

8.  Angiotensin II induces DNA damage via AT1 receptor and NADPH oxidase isoform Nox4.

Authors:  Gholamreza Fazeli; Helga Stopper; Reinhard Schinzel; Chih-Wen Ni; Hanjoong Jo; Nicole Schupp
Journal:  Mutagenesis       Date:  2012-07-27       Impact factor: 3.000

Review 9.  The renin angiotensin aldosterone system and insulin resistance in humans.

Authors:  Patricia C Underwood; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

10.  Triglyceride-based screening tests fail to recognize cardiometabolic disease in African immigrant and African-American men.

Authors:  Sophia S K Yu; Natalie L M Ramsey; Darleen C Castillo; Madia Ricks; Anne E Sumner
Journal:  Metab Syndr Relat Disord       Date:  2012-12-05       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.